Insider Bets Paying Off At SRPT As New 52-Week High Reached

In trading on Wednesday, shares of Sarepta Therapeutics Inc (SRPT) touched a new 52-week high of $33.16/share. That's a 192.67% rise, or $21.83 per share from the 52-week low of $11.33 set back on 01/14/2015. That means at today's intraday high, any investor who purchased SRPT stock any time over the past 52 weeks has an unrealized gain, including company insiders.

Over the past six months, insiders have been scooping up shares, and those bets are now paying off handsomely. As summarized by the table below, SRPT has seen 2 different instances of insiders buying over the trailing six month period.

START SLIDESHOW:
Ten Bargains You Can Buy Cheaper Than The Insiders Did »

Purchased Insider Title Shares Price/Share Value
02/27/2015 Edward M. Kaye, M.D. SVP & Chief Medical Officer 800 $11.81 $9,452.00
02/27/2015 Nishan Garabedian Christopher President and CEO 800 $11.81 $9,452.00

The chart below shows where SRPT has traded over the past year, with the 50-day and 200-day moving averages included.

Sarepta Therapeutics Inc Moving Averages Chart

In afternoon trading on Wednesday, SRPT shares are changing hands at $32.64/share, slightly below the new 52-week high.

More from Stocks

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

GE Is Too Opaque, Too Diversified and Too Poorly Managed: Doug Kass Insider

GE Is Too Opaque, Too Diversified and Too Poorly Managed: Doug Kass Insider

Google's YouTube in Hot Water Again Over Ads on Inappropriate Content

Google's YouTube in Hot Water Again Over Ads on Inappropriate Content

Should Tesla Nominate a New CEO Not Named Elon Musk?

Should Tesla Nominate a New CEO Not Named Elon Musk?